567 related articles for article (PubMed ID: 21880336)
1. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
[TBL] [Abstract][Full Text] [Related]
2. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.
De Stefano N; Curtin F; Stubinski B; Blevins G; Drulovic J; Issard D; Shotekov P; Gasperini C;
Mult Scler; 2010 Jul; 16(7):888-92. PubMed ID: 20200197
[TBL] [Abstract][Full Text] [Related]
3. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Cohen BA; Rivera VM
Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
[TBL] [Abstract][Full Text] [Related]
4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
5. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
[TBL] [Abstract][Full Text] [Related]
6. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
7. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
Giovannoni G; Barbarash O; Casset-Semanaz F; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Mult Scler; 2009 Feb; 15(2):219-28. PubMed ID: 18755819
[TBL] [Abstract][Full Text] [Related]
11. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
12. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
[TBL] [Abstract][Full Text] [Related]
13. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
[TBL] [Abstract][Full Text] [Related]
16. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ;
Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
[TBL] [Abstract][Full Text] [Related]
17. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
Oger J; Francis G; Chang P;
J Neurol Sci; 2005 Oct; 237(1-2):45-52. PubMed ID: 16026803
[TBL] [Abstract][Full Text] [Related]
18. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
